Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Biomarker Identified for Smoker’s Lung Cancer

By Labmedica International staff writers
Posted on 03 Oct 2013
Image: Immunohistochemical analysis of pulmonary adenocarcinoma stained for ASCL1 (Photo courtesy of LifeSpan BioSciences).
Image: Immunohistochemical analysis of pulmonary adenocarcinoma stained for ASCL1 (Photo courtesy of LifeSpan BioSciences).
A specific pair of proteins may be a successful prognostic biomarker for identifying smoking-related lung cancers, especially pulmonary adenocarcinoma.

The protein achaete-scute homolog 1 (ASCL1) is an important regulatory transcription factor in pulmonary neuroendocrine (NE) cell development, but its value as a biomarker of NE differentiation and as a potential prognostic biomarker remains unclear.

Scientists at the Mayo Clinic (Rochester, MN, USA) examined ASCL1 expression in lung cancer samples of varied histologic subtype, clinical outcome, and smoking status and compared with expression of traditional NE markers. ASCL1 messenger ribonucleic acid (mRNA) expression was found almost exclusively in smokers with adenocarcinoma, in contrast to nonsmokers and other lung cancer subtypes.

Analysis of a compendium of 367 microarray-based gene expression profiles in stage I lung adenocarcinomas identified significantly higher expression levels of the rearranged during transfection (RET) oncogene in ASCL1-positive tumors (ASCL1+) compared with ASCL1− tumors. ASCL1 protein expression by immunohistochemical (IHC) analysis correlated best with synaptophysin compared with chromogranin and the cluster of differentiation CD56 and the neural cell adhesion molecule (CD56/NCAM).

High levels of RET expression in ASCL1+, but not in ASCL1- tumors, was associated with significantly shorter overall survival in stage 1 and in all adenocarcinomas. RET protein expression by IHC had an association with overall survival in the context of ASCL1 expression. When scientists blocked the ASCL1 protein in lung cancer-cell lines expressing both genes, the level of RET decreased and tumor growth slowed. This leads them to believe this mechanism will be a promising target for potential drugs and a strong candidate for clinical trials.

George Vasmatzis, PhD, molecular medical scientist and senior author on the study, said “This is exciting because we’ve found what we believe to be a ‘drugable target’ here. It’s a clear biomarker for aggressive adenocarcinomas. These are the fast-growing cancer cells found in smokers’ lungs.” The study was published on September 16, 2013, in the journal Oncogene.

Related Links:
Mayo Clinic



77 ELEKTRONIKA
DIASYS DIAGNOSTIC SYSTEMS
KARL HECHT GMBH & CO KG

Channels

Hematology

view channel
Image: The ADVIA 2120 Hematology System (Photo courtesy of Siemens).

Preoperative Blood Cell Ratios Predict Endometrial Cancer Survival

The variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies and the host response to malignant tumors is characterized by... Read more

Immunology

view channel
Image: Long-lived plasma cells have a distinctive \"fried egg\" appearance, containing bubble-like vacuoles or lipid droplets, which are generally rare in bone marrow cell samples (Photo courtesy of Emory University).

Long-Lived Antibody-Producing Cells Identified in Bone Marrow

A distinct set of long-lived antibody-producing cells have been identified in the human bone marrow that function as an immune archive. These cells keep a catalog of how an adult's immune system responded... Read more

Lab Tech.

view channel
Image: Verigene System instrumentation consists of a Verigene Reader and one or multiple Verigene Processor SPs (Photo courtesy of Nanosphere).

Directed Molecular Diagnostic Tests Highlight Recent Microbiology Conference

The performance of a series of directed molecular diagnostic tests was confirmed by several studies presented at a recent microbiology conference. Nanosphere (Northbrook, IL, USA) manufactures tests... Read more

Industry News

view channel

Cancer Genetics Expands Access to Proprietary Diagnostics Through Agreement with Harvard Pilgrim

Under the terms of a new agreement between Cancer Genetics, Inc. (CGI; Morrisville, NC, USA) and Harvard Pilgrim Healthcare (Hartford, CT; USA), a health care network covering over one million people throughout Massachusetts, Connecticut, and Maine, CGI will offer its cancer diagnostic services to individuals covered under... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.